3 May 2007: GE Healthcare a unit of General Electric (NYSE: GE), announced today that it has completed a license agreement with Nordiag ASA, (OSE: NORD) granting Nordiag ASA access to GE Healthcare patents for the biomagnetic isolation of nucleic acids.  The license, which is valid for the lifetime of the patents, grants Nordiag ASA certain rights with respect to the isolation and purification of nucleic acids using GE Healthcare`s proprietary magnetic separation technology.

GE Healthcare`s patented methods for magnetic separation offer significant advantages over conventional techniques for the isolation and purification of biomolecules such as DNA and RNA from laboratory and clinical samples.  In particular, the proprietary protocols will allow diagnosis from smaller-volume patient samples because they increase the yield of nucleic acid from disease-causing pathogens isolated from patient samples.

`This license recognizes the considerable value that our biomagnetic isolation technology can bring to the diagnosis of infectious diseases,` said Eric Roman, General Manager, Genomic Sciences, GE Healthcare.  `We are pleased to grant Nordiag ASA access to our patents in this area, which will allow them to commercialise products that can isolate nucleic acids from difficult clinical samples.`

`The license from GE Healthcare is important for us since it enables us to widen our portfolio of products for clinical diagnostics,` said Mårten Wigstøl, CEO, NorDiag. `It also shows that we have the capability to bring in external technologies from large players such as GE Healthcare to strengthen our technology base.`

GE Healthcare has an active program to grant licenses for access to its patents for biomagnetic isolation. Financial terms were not disclosed.

About GE Healthcare
GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Our expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, performance improvement, drug discovery, and biopharmaceutical manufacturing technologies is helping clinicians around the world re-imagine new ways to predict, diagnose, inform, treat and monitor disease, so patients can live their lives to the fullest.

GE Healthcare`s broad range of products and services enable healthcare providers to better diagnose and treat cancer, heart disease, neurological diseases and other conditions earlier. Our vision for the future is to enable a new `early health` model of care focused on earlier diagnosis, pre-symptomatic disease detection and disease prevention. Headquartered in the United Kingdom, GE Healthcare is a $17 billion unit of General Electric Company (NYSE: GE). Worldwide, GE Healthcare employs more than 46,000 people committed to serving healthcare professionals and their patients in more than 100 countries. For more information about GE Healthcare, visit our website at www.gehealthcare.com.

About NorDiag ASA:
NorDiag is a biotechnology company with focus on gene based diagnostics in the fields of cancer and infectious diseases.  The Company`s first product in cancer diagnosis is Genefec TM for diagnosis of colorectal cancer. The company has other applications for diagnosis of cancer under development, among others a screening product for colorectal cancer. In addition the company has a product for automated sample preparation of sexually transmitted diseases, as well as applications for other infectious diseases in the product pipeline.

Contact:

NorDiag
CEO Mårten Wigstøl
morten@nordiag.com
+47 91165775

GE Healthcare International
Conor McKechnie
+44 1494 498 276
+44 771 751 7028
conor.mckechnie@ge.com

GE Healthcare Americas
Arvind Gopalratnam
+1 414 721 2429
+1 262 501 0777
arvind.gopalratnam@ge.com

Read the notice in Norwegian here